Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time of Completion: 30 minutes
Description
A Slip of Lip Can Sink the Ship - Four Letter Words in Myeloid Malignancies – ICUS, CHIP and CCUS webcast, part of the Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies online series, will summarize the prognostic implications and treatment considerations for ICUS, CHIP, and CCUS.
Learning Objective
- Summarize the prognostic implications and treatment considerations for idiopathic cytopenia of undetermined significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenias of undetermined significance (CCUS).
Target Audience
This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
Activity Director and Faculty
Activity Director
Matt Kalaycio, MD
Chair, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Faculty
Luca Malcovati, MD
Associate Professor of Hematology
Department of Molecular Medicine
University of Pavia
Pavia, Italy
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Matt Kalaycio, MD
Luca Malcovati, MD |
Acknowledgment
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:
Alexion Pharmaceuticals, Inc.
Apellis Pharmaceuticals
Celgene Corporation
Geron Corporation
Millennium Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
RA Pharmaceuticals, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.
